To elucidate the mechanism by which tranilast inhibits hepatic steatosis, inflammation, and fibrosis induced by HFHC and MCD diets, KEGG pathway enrichment analysis of RNA-seq data revealed that tranilast exerts its effects primarily through the activation of the AMPK pathway. This evidence concerns the gene PRKAA1 and fatty liver disease.